[IDEC-152 was developed to decrease the body's response to allergens, thereby affecting diseases related to asthma and allergic disorders. This monoclonal antibody binds to the CD23 receptor, by which IDEC-152 may favorably influence asthma through its selective regulation of IgE production and its inhibition of other inflammatory pathways. ( NCI )]
UMLS (NCI) C1327944Lumiliximab
Monoclonal Antibody IDEC-152
p5E8
- Amino Acid, Peptide, or Protein
- Pharmacologic Substance
- Immunologic Factor